Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GSK starts phase 3 study of RSV maternal candidate vaccine
RSV is a leading cause of respiratory infections such as bronchiolitis and viral pneumonia in infants.
Read more -
GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age
The results of the TEACH study were presented during the American Society of Tropical Medicine & Hygiene 2020 virtual annual meeting.
Read more -
ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention
This is intended to facilitate the development and expedite the review of drugs that address serious or life-threatening medical conditions.
Read more -
GSK presents Phase 2b data on linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC)
The Phase 2b GLIMMER study was presented today at The Liver Meeting® 2020.
Read more -
ViiV Healthcare announces CHMP positive opinion for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe
This CHMP positive opinion paves the way to expand the use of dolutegravir in a younger population.
Read more -
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial with GSK’s pandemic adjuvant.
Read more -
GSK highlights progress from the BLENREP (belantamab mafodotin-blmf) development programme in multiple myeloma at ASH Annual Meeting
Studies presented will demonstrate belantamab mafodotin's potential in combination with standard therapies in earlier lines of treatment.
Read more -
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women
The study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).
Read more -
GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030
The new goals support GSK's aim to create long-term value for shareholders and meet the needs of society.
Read more -
GSK Nucala (mepolizumab) filings accepted by European Medicines Agency for three additional eosinophil-driven diseases
If approved in the EU, Nucala would be the only treatment indicated for four eosinophil-driven diseases.
Read more -
European Commission approves Zejula (niraparib) as first-line monotherapy maintenance treatment in advanced ovarian cancer
The European Commission has approved Zejula as first-line monotherapy maintenance treatment for adult patients with advanced ovarian cancer.
Read more -
GSK delivers resilient performance, strong commercial execution and further strategic progress in Q3
GSK delivers resilient performance, strong commercial execution and further strategic progress in Q3
Read more -
Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
COVAX Facility is led by Gavi and aims to secure successful and equitable access to COVID-19 vaccines worldwide.
Read more -
ViiV Healthcare presents continued positive findings from first-ever implementation science study on integrating an investigational once-monthly injectable HIV treatment into US healthcare practices
These findings build on recently presented healthcare provider and clinical staff survey perspectives.
Read more -
ViiV Healthcare presents positive new findings from two studies of its investigational, long-acting regimen of cabotegravir and rilpivirine, including five-year data showing long-term durability, efficacy, safety, and tolerability
Positive new findings from two studies of the investigational, long-acting regimen of cabotegravir and rilpivirine for treatment of HIV.
Read more -
ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19 across its clinical development programme for investigational, long-acting cabotegravir and rilpivirine
ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19
Read more -
GSK presents positive clinical data on maternal and older adults RSV candidate vaccines
Phase I/II data presented at ID Week show the two FDA fast-tracked candidate vaccines trigger robust immune response and are well-tolerated
Read more -
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
Long-acting regimen is based on co-administration of cabotegravir and rilpivirine injections once-monthly or once every 2-months
Read more -
ViiV Healthcare presents long-term switch data for Dovato demonstrating non-inferior efficacy in adults with HIV-1 and zero cases of virologic failure versus continuation of a 3-drug TAF-based regimen
The TANGO 96-week data presented at HIV Glasgow 2020 also confirm Dovato’s well-established safety and tolerability profile
Read more -
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
Initial Phase 3 results may be available as early as the end of 2020; complete results are anticipated in January 2021.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
